SCHEMBL982934

SCHEMBL982934

CC(C)(C)OC(=O)n1ccc2cc(C3(Cc4ccccc4)CCN(Cc4ccccc4)C3)ccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
KCNH2 Q12809 1/20 0.42
PDE4A P27815 2/20 0.41
PDE4B Q07343 2/20 0.41
PDE4C Q08493 2/20 0.41
PDE4D Q08499 2/20 0.41
KDM4E B2RXH2 1/20 0.41
KMT2A Q03164 1/20 0.41
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
ACHE P22303 1/20 0.40
NR3C1 P04150 2/20 0.38
NPFFR1 Q9GZQ6 1/20 0.38
NPFFR2 Q9Y5X5 1/20 0.38
TACR1 P25103 1/20 0.38
CCR5 P51681 2/20 0.38
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL985221 0.85 CYP2D6 (0.45) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL982298 0.82 PDE4A (0.39) CYP2D6PDE4APDE4BPDE4CPDE4D
SCHEMBL980851 0.81 MAOA (0.43) CYP2D6SLC6A2SLC6A4SLC6A3PDE4A
SCHEMBL2798825 0.80 PDE4A (0.38) CYP2D6PDE4APDE4BPDE4CPDE4D
SCHEMBL985219 0.79 SLC6A2 (0.64) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL12923048 0.77 CYP2D6 (0.46) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL981974 0.77 CYP2D6 (0.46) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL3043940 0.74 FAAH (0.38) CYP2D6KMT2ATSHRP4HB
SCHEMBL983147 0.73 CYP2D6 (0.44) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL6099616 0.72 NR1H2 (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257545-B1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
EP-2257545-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. Hoffmann-La Roche AG (CH) 2010-12-08 EP disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF SLC6A3, MAOB, TPH2 CYP2D6 97/4885SLC6A2 6/4885SLC6A4 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.